Quintiles Launches China CRO, Kun Tuo

Quintiles Launches China CRO, Kun Tuo

BusinessWire Dec. 13, 2011

Further deepening its commitment to China, Quintiles today announced the launch of Kun Tuo, a local contract research organization (CRO) built to service the unique needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in China.

Building on Quintiles' unmatched success at the global level and experience in conducting clinical trials in China since 1997, Kun Tuo will focus on developing customized solutions to help local and global biopharma companies achieve successful registration of new medicines in China.

Kun Tuo will provide a full range of services, including comprehensive clinical trial management, regulatory submission preparation, biostatistics and data management. Kun Tuo will tap Quintiles' global resources and expertise to develop customized offerings in key therapeutic areas, along with vaccines, late phase studies, medical devices and diagnostics.

"Kun Tuo will leverage Quintiles' quality and training systems to offer customized, high-quality solutions best suited for local Chinese biopharma, as well as global biopharma local affiliates," said Ling Zhen, General Manager, Quintiles China. "We have an aggressive growth plan for China and anticipate doubling Quintiles total staff during 2012 as we look to provide our customers with the solutions they need to succeed in one of the world's most dynamic marketplaces."

Operating in China since 1997, Quintiles China today has more than 300 staff to cover all population centers and study sites in China. With more than 20,000 employees globally operating from offices in 60 countries, Quintiles is the partner of choice for both global and local biopharmaceutical companies to conduct drug development in China.

Quintiles is a recognized industry leader globally, regionally and locally. The company was awarded Best Asia Pacific by Frost & Sullivan in 2009, 2010 and 2011; Best Central Lab in China by the Shanghai Medical Health Center in 2009; and Best CRO by Biopharma Asia 2011.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 24,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

Contacts

Ogilvy Public Relations Worldwide, Beijing
Alana Huang, +86 10 8520 6595
[email protected]
or
Quintiles
Stacey Hara, +65 9100 1462
Media Relations Asia Pacific
[email protected]
or
Jay Johnson, +1 919 998 2066
Media Relations
[email protected]
or
Greg Connors, +1 919 998 2000
Investor Relations
[email protected]

 

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.